AAV-mediated gene transfer for retinal diseases

Expert Opinion on Biological Therapy

Volumn 6, Issue 12, 2006, Pages 1279-1294

  Allocca, Mariacarmela ^a,b   Tessitore, Alessandra ^a   Cotugno, Gabriella ^a,b   Auricchio, Alberto ^a,c  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b European School of Molecular Medicine   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AAV; Gene replacement; Gene silencing; Neurotrophic molecules; Retina; Retinitis pigmentosa

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; ENHANCED GREEN FLUORESCENT PROTEIN; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; X LINKED INHIBITOR OF APOPTOSIS;

ADENO ASSOCIATED VIRUS; ADENOVIRUS VECTOR; CLINICAL TRIAL; CONGENITAL BLINDNESS; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA DEGENERATION; RETINA DISEASE; RETROLENTAL FIBROPLASIA; REVIEW; SEROTYPE; TRANSGENE;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RETINAL DISEASES;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; PRIMATES;

EID: 33845345920     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.12.1279     Document Type: Review

References (187)

1. BERNS KI: Paroviridae: The Viruses and Their Replication. Fields BN (Ed.), Lippincot-Raven, Philadelphia, New York, USA (1996):1017-1042.
2. GAO GP, ALVIRA MR, WANG L et al.: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA (2002) 99(18):11854-11859.
3. GAO G, VANDENBERGHE LH, ALVIRA MR et al.: Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. (2004) 78(12):6381-6388.
4. KOTIN RM, LINDEN RM, BERNS KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. (1992) 11(13):5071-5078.
5. LINDEN RM, WARD P, GIRAUD C, WINOCOUR E, BERNS KI: Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA (1996) 93(21):11288-11294.
6. CHEN CL, JENSEN RL, SCHNEPP BC et al.: Molecular characterization of adeno-associated viruses infecting children. J. Virol. (2005) 79(23):14781-14792.
7. SCHNEPP BC, JENSEN RL, CHEN CL, JOHNSON PR, CLARK KR: Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol. (2005) 79(23):14793-14803.
8. RABINOWITZ JE, SAMULSKI J: Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol. (1998) 9(5):470-475.
9. ZOLOTUKHIN S: Production of recombinant adeno-associated virus vectors. Hum. Gene Ther. (2005) 16(5):551-557.
10. MCCARTY DM, YOUNG SM JR, SAMULSKI RJ: Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. (2004) 38:819-845.
11. AURICCHIO A: Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye. Vision Res. (2003) 43(8):913-918.
12. GAO G, VANDENBERGHE LH, WILSON JM: New recombinant serotypes of AAV vectors. Curr. Gene Ther. (2005) 5(3):285-297.
13. CHAO H, LIU Y, RABINOWITZ J et al.: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. (2000) 2(6):619-623.
14. AURICCHIO A, KOBINGER G, ANAND V et al.: Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. (2001) 10(26):3075-3081.
15. SUMMERFORD C, SAMULSKI RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus Type 2 virions. J. Virol. (1998) 72(2):1438-1445.
16. QING K, MAH C, HANSEN J et al.: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. (1999) 5(1):71-77.
17. SUMMERFORD C, BARTLETT JS, SAMULSKI RJ: AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. (1999) 5(1):78-82.
18. KALUDOV N, BROWN KE, WALTERS RW, ZABNER J, CHIORINI JA: Adeno-associated virus serotype 4(AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. (2001) 75(15):6884-6893.
19. DI PASQUALE G, DAVIDSON BL, STEIN CS et al.: Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. (2003) 9(10):1306-1312.
20. ZABNER J, SEILER M, WALTERS R et al.: Adeno-associated virus Type 5(AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. (2000) 74(8):3852-3858.
21. AURICCHIO A, O'CONNOR E, WEINER D et al.: Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J. Clin. Invest. (2002) 110(4):499-504.
22. ZAISS AK, LIU Q, BOWEN GP et al.: Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. (2002) 76(9):4580-4590.
23. ZHANG Y, CHIRMULE N, GAO G, WILSON J: CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J. Virol. (2000) 74(17):8003-8010.
24. BESSIS N, GARCIACOZAR FJ, BOISSIER MC: Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. (2004) 11(Suppl. 1):S10-S17.
25. ZAISS AK, MURUVE DA: Immune responses to adeno-associated virus vectors. Curr. Gene Ther. (2005) 5(3):323-331.
26. RIVIERE C, DANOS O, DOUAR AM: Long-term expression and repeated administration of AAV Type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. (2006) 13(17):1300-1308.
27. MANNO CS, PIERCE GF, ARRUDA VR et al.: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. (2006) 12(3):342-347.
28. MURPHY SL, SABATINO D, MINGOZZI F, EDMONSON S, HIGH K: Cellular immunity to adeno-associated virus capsid attenuates transgene expression in the liver. Mol. Ther. (2006) 13(Suppl. 1):s31.
29. XIAO W, CHIRMULE N, BERTA SC et al.: Gene therapy vectors based on adeno-associated virus Type 1. J. Virol. (1999) 73(5):3994-4003.
30. CHIRMULE N, XIAO W, TRUNEH A et al.: Humoral immunity to adeno-associated virus Type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. (2000) 74(5):2420-2425.
31. GRIEGER JC, SAMULSKI RJ: Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. (2005) 79(15):9933-9944.
32. DUAN D, FISHER KJ, BURDA JF, ENGELHARDT JF: Structural and functional heterogeneity of integrated recombinant AAV genomes. Virus Res. (1997) 48(1):41-56.
33. NAKAI H, STORM TA, KAY MA: Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. (2000) 18(5):527-532.
34. YAN Z, ZHANG Y, DUAN D, ENGELHARDT JF: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA (2000) 97(12):6716-6721.
35. DUAN D, YUE Y, ENGELHARDT JF: Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. (2001) 4(4):383-391.
36. GHOSH A, YUE Y, DUAN D: Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med. (2006) 8(3):298-305.
37. REICH SJ, AURICCHIO A, HILDINGER M et al.: Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum. Gene Ther. (2003) 14(1):37-44.
38. GHOSH A, YUE Y, DUAN D: A novel hybrid system efficiently expands AAv packaging capacity. Mol. Ther. (2006) 13(Suppl. 1):S286.
39. CLARKE G, HEON E, MCINNES RR: Recent advances in the molecular basis of inherited photoreceptor degeneration. Clin. Genet. (2000) 57(5):313-329.
40. SURACE EM, AURICCHIO A: Adeno-associated viral vectors for retinal gene transfer. Prog. Retin. Eye Res. (2003) 22(6):705-719.
41. DINCULESCU A, GLUSHAKOVA L, MIN SH, HAUSWIRTH WW: Adeno-associated virus-vectored gene therapy for retinal disease. Hum. Gene Ther. (2005) 16(6):649-663.
42. HASKINS ME, JEZYK PF, DESNICK RJ et al.: Animal models of mucopolysaccharidosis. Prog. Clin. Biol. Res. (1982) 94:177-201.
43. LIN CT, GOULD DJ, PETERSEN-JONEST SM, SARGAN DR: Canine inherited retinal degenerations: update on molecular genetic research and its clinical application. J. Small Anim. Pract. (2002) 43(10):426-432.
44. CHANG B, HAWES NL, HURD RE et al.: Retinal degeneration mutants in the mouse. Vision Res. (2002) 42(4):517-525.
45. FLANNERY JG, ZOLOTUKHIN S, VAQUERO MI et al.: Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA (1997) 94(13):6916-6921.
46. BENNETT J, MAGUIRE AM, CIDECIYAN AV et al.: Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc. Natl. Acad. Sci. USA (1999) 96(17):9920-9925.
47. RABINOWITZ JE, ROLLING F, LI C et al.: Cross-packaging of a single adeno-associated virus (AAV) Type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. (2002) 76(2):791-801.
48. YANG GS, SCHMIDT M, YAN Z et al.: Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J. Virol. (2002) 76(15):7651-7660.
49. ACLAND GM, AGUIRRE GD, RAY J et al.: Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. (2001) 28(1):92-95.
50. HO TT, MAGUIRE AM, AGUIRRE GD et al.: Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J. Gene Med. (2002) 4(6):613-621.
51. LOTERY AJ, YANG GS, MULLINS RF et al.: Adeno-associated virus Type 5: transduction efficiency and cell-type specificity in the primate retina. Hum. Gene Ther. (2003) 14(17):1663-1671.
52. ACLAND GM, AGUIRRE GD, BENNETT J et al.: Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther. (2005) 12(6):1072-1082.
53. WEBER M, RABINOWITZ J, PROVOST N et al.: Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol. Ther. (2003) 7(6):774-781.
54. ALI RR, REICHEL MB, DE ALWIS M et al.: Adeno-associated virus gene transfer to mouse retina. Hum. Gene Ther. (1998) 9(1):81-86.
55. SURACE EM, AURICCHIO A, REICH SJ et al.: Delivery of adeno-associated virus vectors ro the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. J. Virol. (2003) 77(14):7957-7963.
56. GLUSHAKOVA LG, TIMMERS AM, ISSA TM et al.: Does recombinant adeno-associated virus-vectored proximal region of mouse rhodopsin promoter support only rod-type specific expression in vivo? Mol. Vis. (2006) 12:298-309.
57. CLACKSON T: Regulated gene expression systems. Gene Ther. (2000) 7(2):120-125.
58. RIVERA VM, CLACKSON T, NATESAN S et al.: A humanized system for pharmacologic control of gene expression. Nat. Med. (1996) 2(9):1028-1032.
59. YE X, RIVERA VM, ZOLTICK P et al.: Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 283(5398):88-91.
60. AURICCHIO A, RIVERA V, CLACKSON T et al.: Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol. Ther. (2002) 6(2):238.
61. LEBHERZ C, AURICCHIO A, MAGUIRE AM et al.: Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum. Gene Ther. (2005) 16(2):178-186.
62. MCGEE SANFTNER LH, RENDAHL KG, QUIROZ D et al.: Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol. Ther. (2001) 3(5 Pt 1):688-696.
63. SMITH JR, VERWAERDE C, ROLLING F et al.: Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum. Gene Ther. (2005) 16(9):1037-1046.
64. STIEGER K, LE MEUR G, LASNE F et al.: Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol. Ther. (2006) 13(5):967-975.
65. FOLLIOT S, BRIOT D, CONRATH H et al.: Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single Type 2 adeno-associated viral vector. J. Gene Med. (2003) 5(6):493-501.
66. CREMERS FP, VAN DEN HURK JA, DEN HOLLANDER AI: Molecular genetics of Leber congenital amaurosis. Hum. Mol. Genet. (2002) 11(10):1169-1176.
67. FAZZI E, SIGNORINI SG, SCELSA B, BOVA SM, LANZI G: Leber's congenital amaurosis: an update. Eur. J. Paediatr. Neurol. (2003) 7(1):13-22.
68. MARLHENS F, BAREIL C, GRIFFOIN JM et al.: Mutations in RPE65 cause Lebet's congenital amaurosis. Nat. Genet. (1997) 17(2):139-141.
69. MORIMURA H, FISHMAN GA, GROVER SA et al.: Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc. Natl. Acad. Sci. USA (1998) 95(6):3088-3093.
70. JIN M, LI S, MOGHRABI WN, SUN H, TRAVIS GH: Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell (2005) 122(3):449-459.
71. REDMOND TM, YU S, LEE E et al.: Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat. Genet. (1998) 20(4):344-351.
72. VESKE A, NILSSON SE, NARFSTROM K, GAL A: Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics (1999) 57(1):57-61.
73. PANG JJ, CHANG B, HAWES NL et al.: Retinal degeneration 12(rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol. Vis. (2005) 11:152-162.
74. PANG JJ, CHANG B, KUMAR A et al.: Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol. Ther. (2006) 13(3):565-572.
75. DEJNEKA NS, SURACE EM, ALEMAN TS et al.: in utero gene therapy rescues vision in a murine model of congenital blindness. Mol. Ther. (2004) 9(2):182-188.
76. NARFSTROM K, KATZ ML, BRAGADOTTIR R et al.: Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest. Ophthalmol. Vis. Sci. (2003) 44(4):1663-1672.
77. JACOBSON SG, ACLAND GM, AGUIRRE GD et al.: Safety of recombinant adeno-associated virus Type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. (2006) 13(6):1074-1084.
78. BENNETT J: Commentary: an aye for eye gene therapy. Hum. Gene Ther. (2006) 17(2):177-179.
79. HONG DH, YUE G, ADAMIAN M, LI T: Retinitis pigmentosa GTPase regulator (RPGRr)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. J. Biol. Chem. (2001) 276(15):12091-12099.
80. HONG DH, PAWLYK BS, SHANG J et al.: A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc. Natl. Acad. Sci. USA (2000) 97(7):3649-3654.
81. PAWLYK BS, SMITH AJ, BUCH PK et al.: Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest. Ophthalmol. Vis. Sci. (2005) 46(9):3039-3045.
82. JOMARY C, VINCENT KA, GRIST J, NEAL MJ, JONES SE: Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther. (1997) 4(7):683-690.
83. ALI RR, SARRA GM, STEPHENS C et al.: Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. (2000) 25(3):306-310.
84. SARRA GM, STEPHENS C, DE ALWIS M et al.: Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum. Mol. Genet. (2001) 10(21):2353-2361.
85. SCHLICHTENBREDE FC, DA CRUZ L, STEPHENS C et al.: Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J. Gene Med. (2003) 5(9):757-764.
86. D'CRUZ PM, YASUMURA D, WEIR J et al.: Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum. Mol. Genet. (2000) 9(4):645-651.
87. NANDROT E, DUFOUR EM, PROVOST AC et al.: Homozygous deletion in the coding sequence of the c-mer gene in RCS rats unravels general mechanisms of physiological cell adhesion and apoptosis. Neurobiol. Dis. (2000) 7(6 Pt B):586-599.
88. SMITH AJ, SCHLICHTENBREDE FC, TSCHERNUTTER M et al.: AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol. Ther. (2003) 8(2):188-195.
89. SAUER CG, GEHRIG A, WARNEKE-WITTSTOCK R et al.: Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat. Genet. (1997) 17(2):164-170.
90. MOLDAY LL, HICKS D, SAUER CG, WEBER BH, MOLDAY RS: Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest. Ophthalmol. Vis. Sci. (2001) 42(3):816-825.
91. REID SN, YAMASHITA C, FARBER DB: Retinoschisin, a photoreceptor-secreted protein, and its interaction with bipolar and muller cells. J. Neurosci. (2003) 23(14):6030-6040.
92. WU WW, MOLDAY RS: Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for X-linked retinoschisis. J. Biol. Chem. (2003) 278(30):28139-28146.
93. ZENG Y, TAKADA Y, KJELLSTROM S et al.: RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest. Ophthalmol. Vis. Sci. (2004) 45(9):3279-3285.
94. MIN SH, MOLDAY LL, SEELIGER MW et al.: Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol. Ther. (2005) 12(4):644-651.
95. BASSI MT, SCHIAFFINO MV, RENIERI A et al.: Cloning of the gene for ocular albinism Type 1 from the distal short arm of the X chromosome. Nat. Genet. (1995) 10(1):13-19.
96. INCERTI B, CORTESE K, PIZZIGONI A et al.: Oal knock-out: new insights on the pathogenesis of ocular albinism Type 1. Hum. Mol. Genet. (2000) 9(19):2781-2788.
97. CORTESE K, GIORDANO F, SURACE EM et al.: The ocular albinism Type 1 (OA1) gene controls melanosome maturation and size. Invest. Ophthalmol. Vis. Sci. (2005) 46(12):4358-4364.
98. SURACE EM, DOMENICI L, CORTESE K et al.: Amelioration of both functional and morphological abnormalities in the retina of a mouse model of ocular albinism following AAV-mediated gene transfer. Mol. Ther. (2005) 12(4):652-658.
99. HENNIG AK, OGILVIE JM, OHLEMILLER KK et al.: AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol. Ther. (2004) 10(1):106-116.
100. GRIFFEY M, MACAULEY SL, OGILVIE JM, SANDS MS: AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. (2005) 12(3):413-421.
101. DRYJA T: Retinitis pigmentosa and stationary night blindness. In: The Metabolic and Molecular Bases of Inherited Diseases. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill, New York, NY, USA (2001):5903-5933.
102. KISSELEV OG: Focus on molecules: rhodopsin. Exp. Eye Res. (2005) 81(4):366-367.
103. WANG DY, CHAN WM, TAM PO et al.: Gene mutations in retinitis pigmentosa and their clinical implications. Clin. Chim. Acta (2005)351(1-2):5-16.
104. OLSSON JE, GORDON JW, PAWLYK BS et al.: Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron (1992) 9(5):815-830.
105. NAASH MI, HOLLYFIELD JG, AL-UBAIDI MR, BAEHR W: Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. Proc. Natl. Acad. Sci. USA (1993) 90(12):5499-5503.
106. STEINBERG RH, FLANNERY JG, NAASH MI et al.: Transgenic rat models of inherited degeneration caused by mutant opsin gene. [ARVO abstract]. Invest. Ophthalmol. Vis. Sci. (1996) 37(Suppl.):S698 (Abstract 3190).
107. PETTERS RM, ALEXANDER CA, WELLS KD et al.: Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat. Biotechnol. (1997) 15(10):965-970.
108. MACHIDA S, KONDO M, JAMISON JA et al.: P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. Invest. Ophthalmol. Vis. Sci. (2000) 41(10):3200-3209.
109. TAN E, WANG Q, QUIAMBAO AB et al.: The relationship between opsin overexpression and photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci. (2001) 42(3):589-600.
110. SALIBA RS, MUNRO PM, LUTHERT PJ, CHEETHAM ME: The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J. Cell Sci. (2002) 115(Pt 14):2907-2918.
111. ILLING ME, RAJAN RS, BENCE NF, KOPITO RR: A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. (2002) 277(37):34150-34160.
112. SIOUD M, IVERSEN PO: Ribozymes, DNAzymes and small interfering RNAs as therapeutics. Curr. Drug Targets (2005) 6(6):647-653.
113. FANNING GC, SYMONDS G: Gene-expressed RNA as a therapeutic: issues to consider, using ribozymes and small hairpin RNA as specific examples. Handb. Exp. Pharmacol. (2006) (173):289-303.
114. DOUDNA JA, CECH TR: The chemical repertoire of natural ribozymes. Nature (2002) 418(6894):222-228.
115. DRENSER KA, TIMMERS AM, HAUSWIRTH WW, LEWIN AS: Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. (1998) 39(5):681-689.
116. LEWIN AS, DRENSER KA, HAUSWIRTH WW et al.: Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med. (1998) 4(8):967-971. [Published erratum appears in Nat. Med. (1998) 4(9): 1081].
117. LAVAIL MM, YASUMURA D, MATTHES MT et al.: Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long- term survival and late-stage therapy [In Process Citation]. Proc. Natl. Acad. Sci. USA (2000) 97(21):11488-11493.
118. FARRAR GJ, KENNA PF, HUMPHRIES P: On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J. (2002) 21(5):857-864.
119. FILIPOWICZ W: RNAi: the nuts and bolts of the RISC machine. Cell (2005) 122(1):17-20.
120. WANG Q, LIU M, KOZASA T et al.: Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF proteins. Methods Enzymol. (2004) 389:244-265.
121. MILLINGTON-WARD S, ALLERS C, TUOHY G et al.: Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta. Hum. Mol. Genet. (2002) 11(19):2201-2206.
122. KIANG AS, PALFI A, ADER M et al.: Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol. Ther. (2005) 12(3):555-561.
123. CASHMAN SM, BINKLEY EA, KUMAR-SINGH R: Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther. (2005) 12(15):1223-1228.
124. TESSITORE A, PARISI F, DENTI MA et al.: Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model. Mol. Ther. (2006) 14(5):692-699.
125. DEJNEKA NS, BENNETT J: Gene therapy and retinitis pigmentosa: advances and future challenges. Bioessays (2001) 23(7):662-668.
126. LAVAIL MM, UNOKI K, YASUMURA D et al.: Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl. Acad. Sci. USA (1992) 89(23):11249-11253.
127. LAVAIL MM, YASUMURA D, MATTHES MT et al.: Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. Ophthalmol. Vis. Sci. (1998) 39(3):592-602.
128. CHAUM E: Retinal neuroprotection by growth factors: a mechanistic perspective. J. Cell. Biochem. (2003) 88(1):57-75.
129. LEVEILLARD T, MOHAND-SAID S, LORENTZ O et al.: Identification and characterization of rod-derived cone viability factor. Nat. Genet. (2004) 36(7):755-759.
130. LAU D, MCGEE LH, ZHOU S et al.: Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest. Ophthalmol. Vis. Sci. (2000) 41(11):3622-3633.
131. GREEN ES, RENDAHL KG, ZHOU S et al.: Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18. Mol. Ther. (2001) 3(4):507-515.
132. LAU D, FLANNERY J: Viral-mediated FGF-2 treatment of the constant light damage model of photoreceptor degeneration. Doc. Ophthalmol. (2003) 106(1):89-98.
133. NIR I, KEDZIERSKI W, CHEN J, TRAVIS GH: Expression of Bcl-2 protects against photoreceptor degeneration in retinal degeneration slow (rds) mice. J. Neurosci. (2000) 20(6):2150-2154.
134. HAO W, WENZEL A, OBIN MS et al.: Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat. Genet. (2002) 32(2):254-260.
135. KIM DH, KIM JA, CHOI JS, JOO CK: Activation of caspase-3 during degeneration of the outer nuclear layer in the rd mouse retina. Ophthalmic Res. (2002) 34(3):150-157.
136. DOONAN F, DONOVAN M, COTTER TG: Caspase-independent photoreceptor apoptosis in mouse models of retinal degeneration. J. Neurosci. (2003) 23(13):5723-5731.
137. REX TS, ALLOCCA M, DOMENICI L et al.: Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol. Ther. (2004) 10(5):855-861.
138. LIANG FQ, DEJNEKA NS, COHEN DR et al.: AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol. Ther. (2001) 3(2):241-248.
139. LIANG FQ, ALEMAN TS, DEJNEKA NS et al.: Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol. Ther. (2001) 4(5):461-472.
140. BOK D, YASUMURA D, MATTHES MT et al.: Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exf. Eye Res. (2002) 74(6):719-735.
141. SCHLICHTENBREDE FC, MACNEIL A, BAINBRIDGE JW et al.: Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther. (2003) 10(6):523-527.
142. SIEVING PA, CARUSO RC, TAO W et al.: Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. USA (2006) 103(10):3896-3901.
143. FRASSON M, PICAUD S, LEVEILLARD T et al.: Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Invest. Ophthalmol. Vis. Sci. (1999) 40(11):2724-2734.
144. MCGEE SANFTNER LH, ABEL H, HAUSWIRTH WW, FLANNERY JG: Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol. Ther. (2001) 4(6):622-629.
145. MARTIN KR, QUIGLEY HA, ZACK DJ et al.: Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. (2003) 44(10):4357-4365.
146. SAPIEHA PS, PELTIER M, RENDAHL KG, MANNING WC, DI POLO A: Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury. Mol. Cell. Neurosci. (2003) 24(3):656-672.
147. MCKINNON SJ, LEHMAN DM, TAHZIB NG et al.: Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol. Ther. (2002) 5(6):780-787.
148. LEE P, WANG CC, ADAM IS AP: Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. (1998) 43(3):245-269.
149. MILLER JW, ADAMIS AP, AIELLO LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev. (1997) 13(1):37-50.
150. PIERCE EA, AVERY RL, FOLEY ED, AIELLO LP, SMITH LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl Acad. Sci. USA (1995) 92(3):905-909.
151. DAWSON DW, VOLPERT OV, GILLIS P et al.: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (1999) 285(5425):245-248.
152. GAO G, LI Y, ZHANG D et al.: Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. (2001) 489(2-3):270-276.
153. CIULLA TA, DANIS RP, HARRIS A: Age-related macular degeneration: a review of experimental tteatments. Surv. Ophthalmol. (1998) 43(2):134-146.
154. KRZYSTOLIK MG, AFSHARI MA, ADAMIS AP et al.: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. (2002) 120(3):338-346.
155. DUH EJ, YANG HS, SUZUMA I et al.: Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. (2002) 43(3):821-829.
156. MORI K, DUH E, GEHLBACH P et al.: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. (2001) 188(2):253-263.
157. ADAMIS AP, ALTAWEEL M, BRESSLER NM et al.: Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2006) 113(1):23-28.
158. D'AMICO DJ, PATEL M, ADAMIS AP et al.: Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology (2006) 113(6):1001, e1-e6.
159. ROSENFELD PJ, HEIER JS, HANTSBARGER G, SHAMS N: Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 113(4):632, e1.
160. SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359(6398):843-845.
161. FERRARA N, HOUCK K, JAKEMAN L, LEUNG DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. (1992) 13(1):18-32.
162. KWAK N, OKAMOTO N, WOOD JM, CAMPOCHIARO PA: VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2000) 41(10):3158-3164.
163. ADAMIS AP, MILLER JW, BERNAL MT et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. (1994) 118(4):445-450.
164. MALECAZE F, CLAMENS S, SIMORRE-PINATEL V et al.: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. (1994) 112(11):1476-1482.
165. KENDALL RL, WANG G, THOMAS KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-I, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. (1996) 226(2):324-328.
166. BAINBRIDGE JW, MISTRY A, DEALWIS M et al.: Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. (2002) 9(5):320-326.
167. SMITH LE, WESOLOWSKI E, MCLELLAN A et al.: Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. (1994) 35(1):101-111.
168. CAMPOCHIARO PA: Retinal and choroidal neovascularization. J. Cell. Physiol. (2000) 184(3):301-310.
169. LAI YK, SHEN WY, BRANKOV M et al.: Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. (2002) 9(12):804-813.
170. LAI CM, DUNLOP SA, MAY LA et al.: Generation of transgenic mice with mild and severe retinal neovascularisation. Br. J. Ophthalmol. (2005) 89(7):911-916.
171. LAI CM, SHEN WY, BRANKOV M et al.: Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. (2005) 12(4):659-668.
172. MORI K, GEHLBACH P, YAMAMOTO S et al.: AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2002) 43(6):1994-2000.
173. RAISLER BJ, BERNS KI, GRANT MB, BELIAEV D, HAUSWIRTH WW: Adeno-associated virus rype-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc. Natl. Acad. Sci. USA (2002) 99(13):8909-8914.
174. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315-328.
175. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277-285.
176. QI JH, EBRAHEM Q, MOORE N et al.: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. (2003) 9(4):407-415.
177. MENESES PI, HAJJAR KA, BERNS KI, DUVOISIN RM: Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model. Gene Ther. (2001) 8(8):646-648.
178. CAO Y, O'REILLY MS, MARSHALL B et al.: Expression of angiostatin cDNA in a marine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. (1998) 101(5):1055-1063.
179. LAI CC, WU WC, CHEN SL et al.: Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. (2001) 42(10):2401-2407.
180. AURICCHIO A, BEHLING K, MAGUIRE A et al.: Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol. Ther. (2002) 6(4):490.
181. MORI K, ANDO A, GEHLBACH P et al.: Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am. J. Pathol. (2001) 159(1):313-320.
182. ZHANG S, KACHI S, HACKETT SF et al.: Engineered zinc finger protein transcription factors as a potential therapy for choroidal neovascularization. American Society of Gene Therapy 9th Annual Meeting. Baltimore, MD, USA (31 May-4 June 2006).
183. BOAST K, BINLEY K, IQBALL S et al.: Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum. Gene Ther. (1999) 10(13):2197-2208.
184. BAINBRIDGE JW, MISTRY A, BINLEY K et al.: Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization. Gene Ther. (2003) 10(12):1049-1054.
185. CHEVEZ-BARRIOS P, CHINTAGUMPALA M, MIELER W et al.: Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J. Clin. Oncol. (2005) 23(31):7927-7935.
186. CAMPOCHIARO PA, NGUYEN QD, SHAH SM et al.: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther. (2006) 17(2):167-176.
187. JACOBSON SG, ALEMAN TS, CIDECIYAN AV et al.: Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc. Natl. Acad. Sci. USA (2005) 102(17):6177-6182.